Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial

Area of Science:

• Hepatology and Viral Gastroenterology
• Oxidative Stress and Antioxidant Research

Background:

• Chronic hepatitis C (HCV) infection is associated with increased oxidative stress.
• Interferon-alpha (IFN) is a standard treatment, but its efficacy can be limited.
• Antioxidant supplementation is explored as an adjunct therapy to improve IFN outcomes.

Purpose of the Study:

• To evaluate the efficacy of antioxidative co-therapy combined with IFN-alpha in naive chronic hepatitis C patients.
• To assess the impact of N-acetylcysteine (NAC), sodium selenite, and vitamin E on treatment response and oxidative stress markers.

Main Methods:

• Randomized trial involving 24 IFN-naive chronic hepatitis C patients.
• Groups received IFN monotherapy, IFN plus NAC and selenium, or IFN plus NAC, selenium, and vitamin E for 24 weeks.
• Evaluated changes in liver histology, viral RNA, ALT normalization, and various oxidative stress biomarkers (glutathione, selenium, vitamin E, TEAC, TBARS, protein carbonyls).

Main Results:

• Baseline increased oxidative stress (low TEAC, high TBARS) was not altered by antioxidant supplementation.
• Complete response rates were 3/8 (IFN alone), 2/8 (IFN+NAC+Se), and 6/8 (IFN+NAC+Se+Vit E).
• Vitamin E group showed a 2.4-fold greater chance of complete response and significantly reduced viral load (P=0.028); however, liver histology did not improve significantly.
• Relapses occurred in 7/11 responders within 6 months post-therapy.

Conclusions:

• No overall beneficial effect of combined antioxidant and IFN therapy was detected for chronic hepatitis C.
• Vitamin E supplementation demonstrated a trend towards improved outcomes, warranting further investigation as an adjuvant to IFN therapy.
• Further studies are needed to confirm the role of vitamin E in enhancing IFN treatment efficacy for chronic hepatitis C.